Aptalis Pharmaceutical Technologies: Press Releases
Aptalis Pharma Announces FDA Approval of NDA for Oral Powder Formulation of Viread®, Co-Developed with Gilead Sciences
Aptalis Pharma has announced that the US Food and Drug Administration (FDA) has approved a new drug application (NDA) for Gilead Sciences' Viread® (tenofovir disoproxil fumarate) oral powder...
PharmaTelevision Interview to Spotlight Aptalis Pharma President John Fraher
Company strategy, portfolio development and emerging markets are just a few of the topics that John Fraher, president of Aptalis Pharma, is scheduled to address during an on-air interview...
Aptalis Pharmaceutical Technologies to Host Webinar: Competitive Advantages of Intelligent Formulation Design
At a time when difficult to formulate molecules and a decline of new chemical entities (NCEs) for new therapies have resulted in pipeline gaps, weakened product portfolios and a challenging...
Eurand to Discuss Strategic Decision-Making at BioEurope Spring
Steve Ellul, Eurand's director of licensing, will discuss aspects of the company's growth strategy during the session 'Understanding the Drivers for Strategic Decision-Making' at BioEurope...
Eurand Enters Agreement With Nycomed for ZENPEP in Russia-CIS
Eurand, a global specialty pharmaceutical company, and Nycomed, a privately owned global pharmaceutical company, have announced an exclusive commercialization, license and supply agreement...
Eurand Presents Taste-Masking Technology Webinar
Eurand, a global specialty pharmaceutical company, has conducted a webinar titled 'The $10 Billion Gap: Leveraging Taste-Masking Technologies to Meet Global Patient Needs', presented by...
Eurand Reports Recent Highlights and Second Quarter 2010 Financial Results
Eurand, a global specialty pharmaceutical company, today reported revenues for the second quarter of 2010 of €32.9m ($40.5m), an increase of 8%, or 3% in constant currency, from the...
Eurand Announces Data on Switching Cystic Fibrosis Patients With Exocrine Pancreatic Insufficiency to FDA-Approved ZENPEP
Eurand Pharmaceuticals, a subsidiary of global specialty pharmaceutical company Eurand, today announced additional data from a post-hoc analysis of a Phase III clinical trial with...
Eurand Names Former Solvay Executive Jean-Louis Anspach President of US Pharmaceuticals Business
Eurand, a global specialty pharmaceutical company, today announced the appointment of Jean-Louis Anspach as president, Eurand Pharmaceuticals, Inc. (EPI). Anspach is a 25-year veteran of...
Eurand Issued US Patent for ZENPEP (pancrelipase) Delayed-Release Capsules
Eurand, a global specialty pharmaceutical company, announced today the grant of US Patent No. 7,658,918, titled 'Stable digestive enzyme compositions', by the United States Patent and...
Eurand Successfully Completes Registration Procedure for Paracetamol ODT 250mg and 500mg in the European Union
Eurand, a specialty pharmaceutical company that develops enhanced pharmaceutical and biopharmaceutical products based on its proprietary pharmaceutical technologies, announced today that the...
Eurand Announces FDA Approval of EUR-1048 (Lamictal ODT), Co-Developed With GlaxoSmithKline
Eurand, a specialty pharmaceutical company that develops enhanced pharmaceutical and biopharmaceutical products based on its proprietary pharmaceutical technologies, today announced that the...
Eurand Initiates the Second of Two Phase III Studies for EUR-1008 In Patients With Pancreatic Insufficiency
Eurand, a specialty pharmaceutical company, today announced the initiation of the second of two Phase III clinical trials required for registration of its Pancreatic Enzyme Product (PEP),...
Twitter